High price blocks access to PrEP drugs
Prices of preexposure prophylaxis drugs to prevent HIV rose an
average of 5% annually between 2014 and 2018, putting the drugs out of reach
even for some people with insurance, researchers reported in the Annals of
Internal Medicine. Insurers cover about 94% of PrEP costs, but many consumers still
struggle with out-of-pocket costs because list prices are so high, says study
author Nathan Furukawa.
Full Story: HealthDay
News (9/10)
No comments:
Post a Comment